Grants / Department of Health and Human Services / National Institutes of Health

RFA-AG-22-028: Limited Competition:Caenorhabditis Intervention Testing Program Data Coordinating Center (U24 Clinical Trial Not Allowed)

Closed Closed October 27, 2021 Opportunity RFA-AG-22-028 ☆ Save

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.

• Award ceiling$200,000
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to small businesses.

• Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See Funding Opportunity Announcement for Full Eligibility Details. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

More grants for small businesses.

Is this a realistic fit?

• Projects NIH funded under this notice had a median yearly award of $290,301; it allows up to $200,000 per award.
• Most of the program's money (73% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The purpose of this Funding Opportunity Announcement (FOA) is to maintain the Data Coordinating Center (DCC) for the Caenorhabditis Intervention Testing Program (CITP,) to coordinate data collection and analysis among the laboratories participating in the CITP, and to provide public access to standard operating procedures and experimental outcomes (including an accessible, annotated, and user-friendly database). The purpose of the CITP is to test, under standardized conditions at a consortium of three sites, potential intervention strategies that may moderate/alleviate health declines associated with aging across genetically diverse species and strains of Caenorhabditis. The CITP will continue to use lifespan and indicators of locomotory health as criteria for efficacious impact by targeting mechanisms likely to be conserved across phyla, but will combine compound sets derived from multiple sources, including those proposed by the biology of aging research community. The goals of next phase of the CITP are to: 1) increase the capacity to screen compounds with a high standard of rigor and reproducibility; 2) evaluate and, if warranted, implement new technologies, protocols, and genetic models of Caenorhabditis to enhance the throughput and depth of the CITP; 3) measure transcriptomic profiles to provide additional information on compounds that are effective in multiple species and/or strains, or on compounds that are effective in only a subset of species or strains; 4) develop reporters of various aging hallmarks in genetically diverse Caenorhabditis strains; and 5) use identified reporters to develop phenotypic screens against hallmarks of aging as a novel paradigm for anti-aging compounds that can have multiple uses in basic research as well as generate unique platforms for translational research.

Category: Health.

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.